David T Yang

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. pmc Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
    David T Yang
    Department of Pharmacology, University of Wisconsin School of Medicine and Public Health, Madison, USA
    Mol Cancer 7:40. 2008
  2. pmc Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell lymphoma
    David T Yang
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, USA
    Appl Immunohistochem Mol Morphol 19:62-9. 2011
  3. pmc Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)
    Julie E Chang
    University of Wisconsin, Madison, WI
    Blood 123:1665-73. 2014
  4. pmc Immunohistochemical evaluation of MYC expression in mantle cell lymphoma
    Matthew J Oberley
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, USA
    Histopathology 63:499-508. 2013
  5. pmc TPL2 kinase regulates the inflammatory milieu of the myeloma niche
    Chelsea Hope
    Department of Medicine, Division of Hematology Oncology, University of Wisconsin Madison School of Medicine and Public Health, Madison, WI University of Wisconsin Carbone Cancer Center, Madison, WI
    Blood 123:3305-15. 2014
  6. pmc Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer
    Anne M Traynor
    Department of Medicine and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Lung Cancer 81:138-41. 2013
  7. pmc VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study
    Julie E Chang
    Department of Medicine, School of Medicine and Public Health, The UW Carbone Cancer Center, University of Wisconsin, Madison, WI 53705, USA
    Br J Haematol 155:190-7. 2011

Collaborators

  • Shigeki Miyamoto
  • Brad Kahl
  • Ranjana H Advani
  • Sangbum Choi
  • Ravi Salgia
  • Adam M Petrich
  • Tien Hoang
  • Anne M Traynor
  • Deric L Wheeler
  • Julie E Chang
  • Chelsea Hope
  • Matthew J Oberley
  • Kyungmann Kim
  • Peiman Hematti
  • Fotis Asimakopoulos
  • Elisabeth M Paietta
  • Mitchell R Smith
  • Ellen Hebron
  • Sandra J Horning
  • Ioanna Maroulakou
  • Natalie Callander
  • Erika Heninger
  • Catherine Leith
  • Randy D Gascoyne
  • Marta Chesi
  • Samuel J Ollar
  • Hailun Li
  • Jaehyup Kim
  • P Leif Bergsagel
  • Jeffrey L Jensen
  • Craig Kanugh
  • Gene R Shaw
  • Saurabh A Rajguru
  • Chong Zhang
  • Kreg M Grindle
  • Jennifer Laffin
  • Michael S Huie
  • Jules Blank
  • Natalie S Callander
  • Walter L Longo
  • Leslie A Gilbert
  • Eric S Rogers
  • Jae E Werndli
  • Christopher Peterson
  • Michael Volk
  • Jens C Eickhoff
  • Thomas A McFarland

Detail Information

Publications7

  1. pmc Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
    David T Yang
    Department of Pharmacology, University of Wisconsin School of Medicine and Public Health, Madison, USA
    Mol Cancer 7:40. 2008
    ..While MCL cells have been shown to harbor constitutive NF-kappaB activity, what fraction of this activity in primary MCL samples is sensitive or resistant to inhibition by bortezomib remains unclear...
  2. pmc Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell lymphoma
    David T Yang
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, USA
    Appl Immunohistochem Mol Morphol 19:62-9. 2011
    ....
  3. pmc Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)
    Julie E Chang
    University of Wisconsin, Madison, WI
    Blood 123:1665-73. 2014
    ..This study was registered at www.clinicaltrials.gov as #NCT00433537. ..
  4. pmc Immunohistochemical evaluation of MYC expression in mantle cell lymphoma
    Matthew J Oberley
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, USA
    Histopathology 63:499-508. 2013
    ..To assess the validity and potential clinical utility of evaluating MYC expression by immunohistochemistry (IHC) in mantle cell lymphoma (MCL)...
  5. pmc TPL2 kinase regulates the inflammatory milieu of the myeloma niche
    Chelsea Hope
    Department of Medicine, Division of Hematology Oncology, University of Wisconsin Madison School of Medicine and Public Health, Madison, WI University of Wisconsin Carbone Cancer Center, Madison, WI
    Blood 123:3305-15. 2014
    ..Our results highlight a TLR2/6-dependent TPL2 pathway as novel therapeutic target acting nonautonomously through macrophages to control myeloma progression. ..
  6. pmc Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer
    Anne M Traynor
    Department of Medicine and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Lung Cancer 81:138-41. 2013
    ..We sought to determine if protein expression of nEGFR is prognostic in early stage non-small cell lung cancer (NSCLC)...
  7. pmc VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study
    Julie E Chang
    Department of Medicine, School of Medicine and Public Health, The UW Carbone Cancer Center, University of Wisconsin, Madison, WI 53705, USA
    Br J Haematol 155:190-7. 2011
    ..The observed 3-year PFS and OS with VcR-CVAD in MCL were comparable to reported outcomes with more intensive regimens. A cooperative group trial (E1405) is attempting to replicate these promising results...